Appili Therapeutics Inc. (APLIF)
OTCMKTS
· Delayed Price · Currency is USD
0.0220
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT
Appili Therapeutics Company Description
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada.
Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.
The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Appili Therapeutics Inc.
| Country | Canada |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Donald Cilla |
Contact Details
Address: #21-1344 Summer Street Halifax, Ontario B3H 0A8 Canada | |
| Phone | 902 442 4655 |
| Website | appilitherapeutics.com |
Stock Details
| Ticker Symbol | APLIF |
| Exchange | OTCMKTS |
| Share Class | Class A Shares |
| Fiscal Year | April - March |
| Reporting Currency | CAD |
| ISIN Number | CA03783R1073 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Donald D. Cilla Jr., M.B.A., Pharmd | Chief Executive Officer, President and Director |
| Kenneth G. Howling | Chief Financial Officer |
| Dr. Gary S. Nabors Ph.D. | Chief Development Officer |
| Dr. Carl Gelhaus Ph.D. | Director of Non-Clinical Research |
| Arthur Baran | Director of New Product Development |